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Hence, it is unclear whether the benefit of
statins on cardiovascular mortality extends
to advanced elderly patients. These people
comprise the fastest-growing segment of
the population, increasing by about 3%
per year. They tend to experience concomi-
tant chronic illness, shorter life expectancy,
and physical frailty, leading to quality-of-
life and end-of-life issues. Is it beneficial
and cost-effective to treat these very elder-
ly patients for hyperlipidemia?
The first prospective, randomized
trial8 of the use of statins among the elder-
ly examined the impact of pravastatin ther-
apy on primary and secondary prevention
of cardiovascular and cerebrovascular
events for men and women (age 70–82
years), with a history of vascular disease or
with risk factors for vascular disease. The
■ Evidence summary
CAD is the leading cause of death in the
United States and is a significant cause of
mortality and morbidity for those aged 65
years and older. Multiple studies have
demonstrated the value of lipid-lowering
therapy for the primary and secondary
prevention of CAD. Most of these studies
have not been specifically oriented toward
the elderly; however, substantial data from
subgroup analyses of older subjects from
major lipid treatment trials has consistent-
ly demonstrated the beneficial effects of
statin therapy in reducing all cardiovascu-
lar events for patients with known CAD
who are 65 and older.2–7
Unfortunately, randomized trials of
hyperlipidemia treatment with statins have
enrolled few people aged 80 and above.
Should we identify and treat 
hyperlipidemia in the advanced elderly?
No randomized controlled trials exist that identify
and treat hyperlipidemia for advanced elderly
patients (age >80 years). Expert and consensus
guidelines state that hyperlipidemia found in any
patient with coronary artery disease (CAD), or at
risk of CAD, should be treated irrespective of age;
however, evidence is limited to support lowering
lipids for advanced elderly patients with and with-
out known CAD (strength of recommendation: C,
based on expert and consensus guidelines).1
E V I D E N C E - B A S E D A N S W E R
When prescribing lipid-lowering therapy for older
adults, assess competing risks as a function of age 
Many of my patients are over age 82, and these
are precisely the ones for whom additional data 
on the benefits of lipid-lowering would be helpful.
Unfortunately, there are no data on lipid-lowering
therapy in this population. Polypharmacy is a 
concern when caring for elderly patients, as are
the practical difficulties of medication expense and
taking drugs properly. Additionally, because older
patients have many competing risks for death, 
the absolute effect of treating any one problem is
relatively small. When prescribing lipid-lowering
therapy for older adults, as is often the case with
geriatrics, one must assess the “competing risks”
as a function of age and, for now, base the 
treatment decision on these risks rather than 
evidence-based medicine for the evidence is 
not yet available.
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sample of 5804 participants was random-
ized to receive pravastatin 40 mg or place-
bo, followed for an average of 3.2 years,
and monitored for the combined endpoint
of myocardial infarction (MI), stroke, and
CAD death. The study showed 19% (95%
confidence interval [CI], 6–31; P=.006)
proportional reduction in the rate of coro-
nary death or nonfatal MI. The absolute
risk reduction for coronary death or non-
fatal myocardial infarction or nonfatal
stroke was significant (2.2%, number
needed to treat [NNT]=45). Rates of
adverse drug events were similar in the
intervention and control groups.8
Serum cholesterol normally declines
with age; so the benefit of lowering lipids
with medication in this age group is unclear.
Furthermore, a meta-analysis9 showed an
inverse relationship between total serum
cholesterol and all-cause mortality for peo-
ple aged 80 and above, raising the possibil-
ity that lowering cholesterol may be detri-
mental in this age group. Two other cohort
studies10,11 found that low cholesterol was
related to all-cause mortality, even when
adjusted for health status and indicators of
frailty. The reasons for this relationship are
not clear, but some postulated mechanisms
exist. It is possible that lower cholesterol
levels can increase the risk of a variety of
nonatherosclerotic diseases since cholesterol
may play a direct role in immune response.
Alternatively, preclinical diseases, chronic
inflammation, or malnutrition may sup-
press cholesterol levels.4
Recommendations from others
National Cholesterol Education Program
Adult Treatment Panel III guidelines1 out-
line risk identification and management of
hyperlipidemia in all age groups with no
exceptions noted for the very elderly. A
recent scientific statement from the
American Heart Association12 outlined the
data on the implementation of all primary
and secondary prevention guidelines for
the elderly and emphasized that the latest
cholesterol treatment recommendations
should be applied to all eligible adults,
with no exceptions for the very elderly.
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It is unclear
whether the 
benefits of statins
extend to the
advanced elderly
(aged 80 years and
older)
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